Breaking Down Chemours: 7 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Chemours (NYSE:CC) has received mixed analyst ratings over the past three months, with a recent decline in the average 12-month price target from $29.50 to $25.14. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite a decline in revenue growth, Chemours maintains strong profitability with a high net margin and effective debt management.
September 03, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chemours has received mixed analyst ratings, with a recent decline in the average 12-month price target from $29.50 to $25.14. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite a decline in revenue growth, Chemours maintains strong profitability with a high net margin and effective debt management.
The mixed analyst ratings and the reduction in the average price target suggest a neutral short-term impact on Chemours' stock price. While the company faces revenue challenges, its strong profitability and effective debt management provide a counterbalance, leading to a neutral outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100